A new first-line option for advanced-stage anal squamous cell carcinoma



Summary

A novel drug combination of chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab has emerged as a promising new first-line treatment for advanced-stage anal squamous cell carcinoma (ASCC). The INTERLACE trial demonstrated a significant improvement in progression-free survival compared to the standard chemotherapy regimen (cisplatin and fluorouracil). This new regimen offers a less toxic alternative to cisplatin-based chemotherapy, providing a better quality of life for patients while extending the time before the cancer progresses. The findings are significant as ASCC treatment options have been limited, potentially changing the standard of care.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!